Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 7.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 84,468 shares of the medical equipment provider's stock after selling 7,100 shares during the quarter. New York State Teachers Retirement System owned approximately 0.12% of Lantheus worth $8,244,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LNTH. Jones Financial Companies Lllp grew its holdings in Lantheus by 108.3% in the fourth quarter. Jones Financial Companies Lllp now owns 2,273 shares of the medical equipment provider's stock valued at $203,000 after purchasing an additional 1,182 shares during the period. Victory Capital Management Inc. grew its position in shares of Lantheus by 13.4% in the fourth quarter. Victory Capital Management Inc. now owns 87,130 shares of the medical equipment provider's stock valued at $7,795,000 after purchasing an additional 10,297 shares during the period. Assetmark Inc. grew its position in shares of Lantheus by 10.0% in the fourth quarter. Assetmark Inc. now owns 69,059 shares of the medical equipment provider's stock valued at $6,178,000 after purchasing an additional 6,257 shares during the period. Arizona State Retirement System grew its position in shares of Lantheus by 0.9% in the fourth quarter. Arizona State Retirement System now owns 20,137 shares of the medical equipment provider's stock valued at $1,801,000 after purchasing an additional 178 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Lantheus in the fourth quarter valued at about $36,183,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Price Performance

LNTH traded up $3.96 on Tuesday, reaching $83.15. 467,670 shares of the company's stock were exchanged, compared to its average volume of 1,019,521. The stock has a market cap of $5.75 billion, a PE ratio of 23.62 and a beta of 0.12. The stock's fifty day moving average price is $82.10 and its 200-day moving average price is $90.16. Lantheus Holdings, Inc. has a twelve month low of $73.11 and a twelve month high of $126.89. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.69 EPS. Sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

LNTH has been the subject of several research reports. B. Riley cut their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Truist Financial lowered their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $130.50.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.00% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.